These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pergolide-induced retroperitoneal fibrosis. Mondal BK; Suri S Int J Clin Pract; 2000; 54(6):403. PubMed ID: 11092116 [TBL] [Abstract][Full Text] [Related]
7. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease]. Sánchez-Chapado M; Angulo Cuesta J; Guil Cid M; Jiménez FJ; López Alvarez YJ Arch Esp Urol; 1995 Dec; 48(10):979-83. PubMed ID: 8588730 [TBL] [Abstract][Full Text] [Related]
8. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?]. Roth J; Ulmanová O; Růzicka E Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300 [TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Kunkler RB; Osborn DE; Abbott RJ Br J Urol; 1998 Jul; 82(1):147. PubMed ID: 9698685 [No Abstract] [Full Text] [Related]
10. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. Shaunak S; Wilkins A; Pilling JB; Dick DJ J Neurol Neurosurg Psychiatry; 1999 Jan; 66(1):79-81. PubMed ID: 9886458 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Lund BC; Neiman RF; Perry PJ Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093 [TBL] [Abstract][Full Text] [Related]
12. [Sleep attacks and pergolide mesylate]. García Ruiz PJ; Hernández J; Cantarero S; Fanjul S Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938 [No Abstract] [Full Text] [Related]
13. Pergolide-induced pleuropulmonary fibrosis. Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064 [TBL] [Abstract][Full Text] [Related]
14. Medical hazards of the internet: gambling in Parkinson's disease. Larner AJ Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457 [No Abstract] [Full Text] [Related]
16. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease. Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629 [TBL] [Abstract][Full Text] [Related]
17. Dopamine agonists and valvular heart disease. Kast RE; Altschuler EL N Engl J Med; 2007 Apr; 356(16):1677; author reply 1678-80. PubMed ID: 17447278 [No Abstract] [Full Text] [Related]
18. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Hofmann C; Penner U; Dorow R; Pertz HH; Jähnichen S; Horowski R; Latté KP; Palla D; Schurad B Clin Neuropharmacol; 2006; 29(2):80-6. PubMed ID: 16614540 [TBL] [Abstract][Full Text] [Related]
19. [Pergolide-induced pleural effusion in a patient with juvenile parkinsonism]. Kuwabara T Rinsho Shinkeigaku; 2002 Aug; 42(8):757-60. PubMed ID: 12701223 [TBL] [Abstract][Full Text] [Related]
20. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling. Garcia RF; Ordacgi L; Mendlowicz MV; de Freitas GR; Rosso AL; Nazar BP; Fontenelle LF Cogn Behav Neurol; 2007 Mar; 20(1):11-4. PubMed ID: 17356338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]